Adding MR Diffusion Imaging and T2 Signal Intensity to Neck Imaging Reporting and Data System Categories 2 and 3 in Primary Sites of Postsurgical Oral Cavity Carcinoma Provides Incremental Diagnostic Value

References

1. 1.↵
   1. Chang JH,
   2. Wu CC,
   3. Yuan KS, et al

   . Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 2017;8:55600–12 doi:10.18632/oncotarget.16340 pmid:28903447

   CrossRefPubMed
2. 2.↵
   1. Ritoe SC,
   2. Krabbe PFM,
   3. Kaanders JH

   , et al. Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer 2004;101:1382–89 doi:10.1002/cncr.20536 pmid:15368326

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Goodwin WJ

   . Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110:1–18 doi:10.1097/00005537-200003001-00001 pmid:10714711

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Wierzbicka M,
   2. Napierała J

   . Updated National Comprehensive Cancer Network Guidelines for Treatment of Head and Neck Cancers 2010-2017. Otolaryngol Pol 2017;71:1–6 doi:10.5604/01.3001.0010.7193 pmid:29327681

   CrossRefPubMed
5. 5.↵
   1. Gore A,
   2. Baugnon K,
   3. Beitler J, et al

   . Posttreatment imaging in patients with head and neck cancer without clinical evidence of recurrence: should surveillance imaging extend beyond 6 months? AJNR Am J Neuroradiol 2020;41:1238–44 doi:10.3174/ajnr.A6614 pmid:32554418

   Abstract/FREE Full Text
6. 6.↵
   1. Baugnon KL

   . NI-RADS to predict residual or recurrent head and neck squamous cell carcinoma. Neuroimaging Clin N Am 2022;32:1–18 doi:10.1016/j.nic.2021.08.003 pmid:34809832

   CrossRefPubMed
7. 7.↵
   1. Aiken AH,
   2. Farley A,
   3. Baugnon KL, et al

   . Implementation of a novel surveillance template for head and neck cancer: Neck Imaging Reporting and Data System (NI-RADS). J Am Coll Radiol 2016;13:743–46.e1 doi:10.1016/j.jacr.2015.09.032 pmid:26577876

   CrossRefPubMed
8. 8.↵
   1. Dinkelborg P,
   2. Ro SR,
   3. Shnayien S, et al

   . Retrospective evaluation of NI-RADS for detecting postsurgical recurrence of oral squamous cell carcinoma on surveillance CT or MRI. AJR Am J Roentgenol 2021;217:198–206 doi:10.2214/AJR.20.24209 pmid:32876497

   CrossRefPubMed
9. 9.↵
   1. Aiken AH,
   2. Rath TJ,
   3. Anzai Y, et al

   . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS committee. J Am Coll Radiol 2018;15:1097–1108 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

   CrossRefPubMed
10. 10.↵
    1. Elsholtz FH,
    2. Erxleben C,
    3. Bauknecht HC, et al

    . Reliability of NI-RADS criteria in the interpretation of contrast-enhanced magnetic resonance imaging considering the potential role of diffusion-weighted imaging. Eur Radiol 2021;31:6295–6304 doi:10.1007/s00330-021-07693-4 pmid:33533989

    CrossRefPubMed
11. 11.↵
    1. Ashour MM,
    2. Darwish EA,
    3. Fahiem RM, et al

    . MRI posttreatment surveillance for head and neck squamous cell carcinoma: proposed MR NI-RADS criteria. AJNR Am J Neuroradiol 2021;42:1123–29 doi:10.3174/ajnr.A7058 pmid:33707288

    Abstract/FREE Full Text
12. 12.↵
    1. Hwang I,
    2. Choi SH,
    3. Kim YJ, et al

    . Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: application of high b-value diffusion-weighted imaging. AJNR Am J Neuroradiol 2013;34:2343–48 doi:10.3174/ajnr.A3603 pmid:23811978

    Abstract/FREE Full Text
13. 13.↵
    1. Ailianou A,
    2. Mundada P,
    3. De Perrot T, et al

    . MRI with DWI for the detection of posttreatment head and neck squamous cell carcinoma: why morphologic MRI criteria matter. AJNR Am J Neuroradiol 2018;39:748–55 doi:10.3174/ajnr.A5548 pmid:29449279

    Abstract/FREE Full Text
14. 14.↵
    1. Krieger DA,
    2. Hudgins PA,
    3. Nayak GK, et al

    . Initial performance of NI-RADS to predict residual or recurrent head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2017;38:1193–99 doi:10.3174/ajnr.A5157 pmid:28364010

    Abstract/FREE Full Text
15. 15.↵
    1. Wangaryattawanich P,
    2. Branstetter BF,
    3. Ly JD, et al

    . Positive predictive value of neck imaging reporting and data system categories 3 and 4 posttreatment FDG-PET/CT in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2020;41:1070– 75 doi:10.3174/ajnr.A6589 pmid:32467187

    Abstract/FREE Full Text
16. 16.↵
    1. King AD,
    2. Keung CK,
    3. Yu KH, et al

    . T2-weighted MR imaging early after chemoradiotherapy to evaluate treatment response in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2013;34:1237–41 doi:10.3174/ajnr.A3378 pmid:23306012

    Abstract/FREE Full Text
17. 17.↵
    1. Pryor DI,
    2. Porceddu SV,
    3. Scuffham PA, et al

    . Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. Head Neck 2013;35:1287–94 doi:10.1002/hed.23108 pmid:22987817

    CrossRefPubMed
18. 18.↵
    1. Hsu D,
    2. Rath TJ,
    3. Branstetter BF, et al

    . Interrater reliability of NI-RADS on posttreatment PET/contrast-enhanced CT scans in head and neck squamous cell carcinoma. Radiol Imaging Cancer 2021;3:e200131 doi:10.1148/rycan.2021200131 pmid:34018845

    CrossRefPubMed